Atlas Trials

A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC

Clinical trial NCT05236699 · COMPLETED

Trial details

NCT number
NCT05236699
Sponsor
Tongji Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Intrahepatic Cholangiocarcinoma
Start date
2022-02-01
Primary completion
2024-06-30
Enrollment
23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.